title: Treatment of paediatric scalp psoriasis with calcipotriene/betamethasone dipropionate scalp formulation: effectiveness, safety and influence on children's quality of life in daily practice.
abstract: BACKGROUND
  Evidence on efficacy and safety of topical treatments for paediatric scalp psoriasis is lacking.
  
  
  OBJECTIVE
  This study aims to evaluate the effectiveness and safety of calcipotriene/betamethasone dipropionate scalp formulation for paediatric scalp psoriasis in daily clinical practice. The influence of this formulation on the quality of life (QoL) was assessed as well.
  
  
  METHODS
  Data of children treated with the scalp formulation were extracted from a prospective observational daily clinical practice registry of children with psoriasis, called Child-Continuous Assessment of Psoriasis Treatment Use Registry. Severity was expressed by Psoriasis Scalp Severity Index (PSSI) and the impact on the QoL was reflected by the validated Children's Scalpdex in Psoriasis (CSP).
  
  
  RESULTS
  Eighty-four treatment episodes were analysed. Significant improvements of PSSI score (18.7 ± 11.8 to 12.7 ± 9.4) were demonstrated in the first 12 weeks and this result was well maintained during 48 weeks of follow-up. Three patients (4.1%) developed striae of the skin (arms, trunk and legs), which are possibly related to the scalp formulation. CSP scores (79.0-46.3) declined significantly after 3 months.
  
  
  CONCLUSIONS
  In a daily clinical practice cohort of children with scalp psoriasis, calcipotriene/betamethasone dipropionate scalp formulation was effective with a 32.1% improvement of PSSI at week 12 and a maintenance of this effect until 48 weeks of follow-up, in combination with improvement of QoL.
authors.affiliation: Department of Dermatology, Radboud university medical center, Nijmegen, The Netherlands.
authors.forename: A M
authors.initials: AM
authors.lastname: Oostveen
authors.affiliation: Department of Dermatology, Radboud university medical center, Nijmegen, The Netherlands.
authors.forename: E M G J
authors.initials: EM
authors.lastname: de Jong
authors.affiliation: Department for Health Evidence, Radboud university medical center, Nijmegen, The Netherlands.
authors.forename: A R T
authors.initials: AR
authors.lastname: Donders
authors.affiliation: Department for Health Evidence, Radboud university medical center, Nijmegen, The Netherlands.
authors.forename: P C M
authors.initials: PC
authors.lastname: van de Kerkhof
authors.affiliation: Department for Health Evidence, Radboud university medical center, Nijmegen, The Netherlands.
authors.forename: M M B
authors.initials: MM
authors.lastname: Seyger
mesh_terms: D000279:Administration, Cutaneous; D000293:Adolescent; D001623:Betamethasone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002117:Calcitriol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies; D011565:Psoriasis / Q000188:drug therapy*; D011788:Quality of Life; D012536:Scalp Dermatoses / Q000188:drug therapy*; D012720:Severity of Illness Index
chemical_list: D004338:Drug Combinations; C055085:calcipotriene; C011175:betamethasone-17,21-dipropionate; D001623:Betamethasone; D002117:Calcitriol